Sunshine Biopharma (SBFM, Financial) has reported a net loss of $5.13 million for the fiscal year. Despite this, the company's revenue surged significantly, reaching $34.9 million, which represents a 44.8% increase compared to the previous year.
- Sunshine Biopharma's revenue surged by 44.8%, despite a net loss.
- Analysts predict a tremendous potential upside for SBFM's stock price.
- The company received an "Outperform" rating based on brokerage recommendations.
Wall Street Analysts Forecast
According to projections by one analyst, the average price target for Sunshine Biopharma Inc (SBFM, Financial) stands at $300.00, with both high and low estimates at the same level. This suggests an astonishing potential upside of 14,323.08% from the current market price of $2.08. Investors can explore more detailed estimates on the Sunshine Biopharma Inc (SBFM) Forecast page.
Brokerage Firm Recommendation
The consensus recommendation from one brokerage firm for Sunshine Biopharma Inc (SBFM, Financial) is presently 2.0, indicating an "Outperform" rating. The rating scale employed ranges from 1 to 5, with 1 representing a Strong Buy, and 5 indicating a Sell. This reflects the optimism analysts have regarding the company's stock performance.
GuruFocus GF Value Estimate
Sunshine Biopharma Inc (SBFM, Financial) has an estimated GF Value of $2,385.67 for the following year, suggesting a whopping 114,595.67% upside potential from the current price of $2.08. The GF Value is a proprietary metric from GuruFocus, calculated based on the stock's historical trading multiples, business growth history, and future performance estimates. For more comprehensive data, visit the Sunshine Biopharma Inc (SBFM) Summary page.
These projections highlight a promising future for Sunshine Biopharma, making it a stock worth monitoring closely for potential investment opportunities.
